trial
as of 2026-07-01A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
NCTId NCT00621777
at a glance
Phase 4 · Completed
Enrollment 247 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2013-05
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
247 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-02
Primary completion
2013-05
Eligibility
ALL · 18 Years · 70 Years
Interventions & indications
Sponsors
Massachusetts General HospitalLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator
Investigators
1
A. Eden Evins, MD, MPHPrincipal Investigator
Sites
10 total
Birmingham, United StatesBloomington, United StatesBoston, United StatesBoston, United StatesGrand Rapids, United StatesMinneapolis, United StatesClaremont, United StatesConcord, United StatesManchester, United StatesNashua, United States
Facts & assertions
4 sourced
Enrollment
247
Phase
PHASE4
Primary Completion Date
2013-05
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person